SynthesisBMC nephrology2025
Serum chloride concentrations and outcomes in adult patients with cirrhosis: a systematic review and meta-analysis.
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeElectrolyte disturbances, including hyponatremia, are common in cirrhosis, with hyponatremia already incorporated into the MELD-Na score as a prognostic marker. However, the prognostic role of serum chloride, the main extracellular anion, remains underexplored. Emerging evidence suggests hypochloremia is independently associated with increased mortality and acute kidney injury (AKI) in cirrhotic patients. Proposed mechanisms include dysregulated activation of the renin-angiotensin, vasopressin, and sympathetic nervous systems, leading to renal vasoconstriction and impaired function. This systematic review evaluates the association between serum chloride levels and outcomes, including mortality and KDIGO-defined AKI rates, aiming to enhance understanding and inform management strategies.
methodsThis review followed PRISMA guidelines and a PROSPERO-registered protocol (CRD42024550945). Comprehensive searches of MEDLINE, EMBASE, Cochrane, Scopus, and Web of Science were conducted through June 6, 2024, without language restrictions. Controlled vocabulary and keywords were used to identify relevant studies. Two independent reviewers performed title, abstract, and full-text screening, with disagreements resolved through consensus or third-party arbitration. Inter-rater reliability was assessed using Cohen's kappa. Data extraction and risk of bias evaluations were performed using the PROBAST tool. Findings were summarized using a PRISMA flowchart.
resultsFive studies (n = 3,150) were included, primarily retrospective cohorts, with one prospective study. Hypochloremia was defined as serum chloride < 99 mEq/L in most studies, except one, which used < 107.35 mmol/L. Cirrhosis etiologies included alcohol-related liver disease (40-64%), hepatitis B (7.9-59.9%), hepatitis C (7-8.9%), and non-alcoholic fatty liver disease (7-11.7%), with fewer cases of autoimmune and cryptogenic causes. Comorbidities included diabetes mellitus (21.3%), hypertension (13.4%), and varices (72-87%), with 62-99% having a history of decompensation. Extrahepatic organ failures were prevalent, affecting 79.4% of patients, with 31.6% and 13.4% experiencing two and three organ failures, respectively.Meta-analysis showed hypochloremia was significantly associated with increased mortality (pooled OR: 2.52; 95% CI: 1.88-3.39, p < 0.0001). Individual ORs ranged from 2.08 to 17.42, with low to moderate heterogeneity (I² = 36%). Hypochloremia also correlated with elevated creatinine levels and increased AKI prevalence.
conclusionHypochloremia is a strong predictor of mortality and renal dysfunction in cirrhotic patients. Early recognition and management of hypochloremia are critical to improving outcomes in this high-risk population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.